REG-4basebio Plc: Appointment of Joint Corporate Broker

4BasebioAnnouncement

14/11/2024 07:00

14 November 2024

4basebio PLC

("4basebio" or the "Company")

Appointment of Joint Corporate Broker

14 November 2024 – 4basebio PLC (AIM: 4BB) (“4basebio” or the
“Company”), which develops and commercialises the large scale manufacture
of synthetic DNA as well as nanoparticle delivery solutions, announces the
appointment of RBC Capital Markets as the Company's joint corporate broker, to
work alongside Cavendish Capital Markets, with immediate effect.

Enquiries

 4basebio PLC Dr. Heikki Lanckriet                                                      +44 (0)1223 967 943  
 Joint Corporate Broker RBC Capital Markets Rupert Walford / Kathryn Deegan             +44 (0)20 7653 4000  
 Joint Corporate Broker Cavendish Capital Markets Limited Geoff Nash / Nigel Birks      +44 (0)20 7220 0500  
                                                                                                             
 Nominated Adviser Cairn Financial Advisers LLP Jo Turner / Sandy Jamieson / Ed Downes  +44 (0)20 7213 0880  

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.



Copyright (c) 2024 PR Newswire Association,LLC. All Rights Reserved